Clever Culture Systems Ltd Q1 FY27 Cash Flow Report
Key points
- 3 APAS® sales completed and invoiced in Q1 FY27
- H1 FY27 sales and new evaluations expected to reach 8 units
- PSC Biotech appointed Sales Agent for North America and Singapore
- Cash: $1.4 million balance and $3.9 million in expected cash inflows over the next two quarters
Full summary
Clever Culture Systems Ltd, a leader in microbiology automation using artificial intelligence, has released its Quarterly Cashflow report and business update for the quarter ended 30 September 2026. The company reported three APAS® sales completed and invoiced in Q1 FY27 with Novo and AstraZeneca. The company expects H1 FY27 sales and new evaluations to reach 8 units. PSC Biotech has been appointed as a Sales Agent for North America and Singapore, extending the company's market reach. The company has a cash balance of $1.4 million and expected cash inflows of $3.9 million over the next two quarters.
Outlook
The company expects a strong finish to H1 FY27 with potential sales reaching 8 units. The company is also in the final stage of finalizing a purchase commitment from a new single-site pharmaceutical manufacturer.
Summary generated by a large language model. Please interpret with care.